Provention Bio Inc
NASDAQ:PRVB
Intrinsic Value
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. [ Read More ]
The intrinsic value of one PRVB stock under the Base Case scenario is 19.53 USD. Compared to the current market price of 24.98 USD, Provention Bio Inc is Overvalued by 22%.
Valuation Backtest
Provention Bio Inc
Run backtest to discover the historical profit from buying and selling PRVB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Provention Bio Inc
Current Assets | 174.6m |
Cash & Short-Term Investments | 165m |
Receivables | 1.4m |
Other Current Assets | 8.3m |
Non-Current Assets | 62.2m |
PP&E | 2.5m |
Intangibles | 59.6m |
Other Non-Current Assets | 120k |
Current Liabilities | 90.4m |
Accounts Payable | 6.8m |
Accrued Liabilities | 20.8m |
Other Current Liabilities | 62.9m |
Non-Current Liabilities | 24.6m |
Long-Term Debt | 23.5m |
Other Non-Current Liabilities | 1.1m |
Earnings Waterfall
Provention Bio Inc
Revenue
|
12.9m
USD
|
Cost of Revenue
|
-2.6m
USD
|
Gross Profit
|
10.3m
USD
|
Operating Expenses
|
-138.5m
USD
|
Operating Income
|
-128.2m
USD
|
Other Expenses
|
14.6m
USD
|
Net Income
|
-113.6m
USD
|
Free Cash Flow Analysis
Provention Bio Inc
PRVB Profitability Score
Profitability Due Diligence
Provention Bio Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Provention Bio Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
PRVB Solvency Score
Solvency Due Diligence
Provention Bio Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Provention Bio Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRVB Price Targets Summary
Provention Bio Inc
Ownership
PRVB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PRVB Price
Provention Bio Inc
Average Annual Return | 74.94% |
Standard Deviation of Annual Returns | 172.25% |
Max Drawdown | -27% |
Market Capitalization | 2.2B USD |
Shares Outstanding | 94 780 900 |
Percentage of Shares Shorted | 7.58% |
PRVB News
Last Important Events
Provention Bio Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Provention Bio Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. The company is headquartered in Red Bank New Jersey, New Jersey and currently employs 82 full-time employees. The company went IPO on 2018-07-24. The firm's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.
Contact
IPO
Employees
Officers
The intrinsic value of one PRVB stock under the Base Case scenario is 19.53 USD.
Compared to the current market price of 24.98 USD, Provention Bio Inc is Overvalued by 22%.